The results of cellular assays showed that the targeted nanoparticles group (NPs-PAX8-PPARγ) had a higher affinity for thyroid cancer cells compared to the nontargeted group (NPs-Control). The gene discussed is PPARG; the disease is thyroid gland carcinoma.